TScan Therapeutics (TCRX)
(Delayed Data from NSDQ)
$7.32 USD
+0.03 (0.41%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.30 -0.02 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for TScan Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 21 | 14 | 10 | 1 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 21 | 14 | 10 | 1 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 115 | 80 | 59 | 27 | 14 |
Income After Depreciation & Amortization | -93 | -67 | -49 | -26 | -14 |
Non-Operating Income | 8 | 2 | 0 | 0 | 1 |
Interest Expense | 4 | 1 | 0 | 0 | 0 |
Pretax Income | -89 | -66 | -49 | -26 | -14 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -89 | -66 | -49 | -26 | -14 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -89 | -66 | -49 | -26 | -14 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -88 | -61 | -45 | -25 | -14 |
Depreciation & Amortization (Cash Flow) | 5 | 5 | 3 | 1 | 1 |
Income After Depreciation & Amortization | -93 | -67 | -49 | -26 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.60 | 24.05 | 11.66 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.36 | -2.75 | -4.17 | NA | NA |
Diluted Net EPS (GAAP) | -1.36 | -2.75 | -4.17 | -28.52 | NA |
Fiscal Year end for TScan Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 7.21 | 3.89 | 3.15 | 6.80 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 7.21 | 3.89 | 3.15 | 6.80 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 28.57 | 28.63 | 27.76 | 29.55 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -21.36 | -24.74 | -24.61 | -22.75 |
Non-Operating Income | NA | 2.60 | 2.73 | 1.53 | 1.14 |
Interest Expense | NA | 0.85 | 0.98 | 0.97 | 0.96 |
Pretax Income | NA | -19.61 | -23.00 | -24.05 | -22.56 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -19.61 | -23.00 | -24.05 | -22.56 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -19.61 | -23.00 | -24.05 | -22.56 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 94.84 | 94.83 | 47.21 | 24.23 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.24 | -0.51 | -0.93 |
Diluted Net EPS (GAAP) | NA | 0.32 | -0.24 | -0.51 | -0.93 |